Related Experiment Video
Updated: Feb 24, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis
Published on: June 17, 2025
Parathyroid hormone-related protein is a therapeutic target in idiopathic pulmonary fibrosis
Xue-Quan Fang1,2,3, Suha Lim4,5,6, Yoon-Mi Lee1,3
1Department of Medicinal Biosciences, College of Biomedical and Health Science, Konkuk University, Chungju, Republic of Korea.
The crosstalk between immune or alveolar epithelial cells and fibroblasts mediated by paracrine signaling molecules is associated with the pathogenesis of idiopathic pulmonary fibrosis (IPF). However, studies investigating the active involvement of soluble mediators derived from bronchial epithelial cells in fibroblast activation and the development of pulmonary fibrosis are limited. Reanalysis of bulk and single-cell RNA-sequencing data from human bronchus and IPF lung tissue revealed marked upregulation of parathyroid hormone-like hormone (PTHLH) in IPF lung tissue compared with normal tissue, with expression predominantly localized to bronchial epithelial cells. parathyroid hormone-related protein (PTHrP) translated from PTHLH was significantly increased in the bronchial epithelium of IPF patients and bleomycin-induced pulmonary fibrosis mice. Furthermore, the paracrine peptide PTHrP1-34, generated through post-translational processing of PTHrP, was elevated in lung homogenates and bronchoalveolar lavage fluid obtained from fibrotic lungs. Cell- and animal-based experiments showed that PTHrP1-34 activated fibroblasts and extracellular matrix production, resulting in the progression of pulmonary fibrosis. In a preclinical evaluation using a bleomycin-induced pulmonary fibrosis mouse model, attenuating effects against pulmonary fibrosis were observed using neutralizing antibodies, peptides, and gene silencing strategies targeting the PTHrP1-34/parathyroid hormone 1 receptor axis. In conclusion, our results suggest that PTHrP1-34 derived from bronchial epithelial cells is involved in the pathogenesis of IPF and is a promising target for alleviating disease progression.
The crosstalk between immune or alveolar epithelial cells and fibroblasts mediated by paracrine signaling molecules is associated with the pathogenesis of idiopathic pulmonary fibrosis (IPF). However, studies investigating the active involvement of soluble mediators derived from bronchial epithelial cells in fibroblast activation and the development of pulmonary fibrosis are limited. Reanalysis of bulk and single-cell RNA-sequencing data from human bronchus and IPF lung tissue revealed marked upregulation of parathyroid hormone-like hormone (PTHLH) in IPF lung tissue compared with normal tissue, with expression predominantly localized to bronchial epithelial cells. parathyroid hormone-related protein (PTHrP) translated from PTHLH was significantly increased in the bronchial epithelium of IPF patients and bleomycin-induced pulmonary fibrosis mice. Furthermore, the paracrine peptide PTHrP1-34, generated through post-translational processing of PTHrP, was elevated in lung homogenates and bronchoalveolar lavage fluid obtained from fibrotic lungs. Cell- and animal-based experiments showed that PTHrP1-34 activated fibroblasts and extracellular matrix production, resulting in the progression of pulmonary fibrosis. In a preclinical evaluation using a bleomycin-induced pulmonary fibrosis mouse model, attenuating effects against pulmonary fibrosis were observed using neutralizing antibodies, peptides, and gene silencing strategies targeting the PTHrP1-34/parathyroid hormone 1 receptor axis. In conclusion, our results suggest that PTHrP1-34 derived from bronchial epithelial cells is involved in the pathogenesis of IPF and is a promising target for alleviating disease progression.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

